Press coverage about Capricor Therapeutics (NASDAQ:CAPR) has trended somewhat positive this week, Accern reports. The research group identifies positive and negative news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Capricor Therapeutics earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 46.4385751715165 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the news stories that may have effected Accern Sentiment Analysis’s scoring:

Shares of Capricor Therapeutics (NASDAQ CAPR) traded down $0.02 during mid-day trading on Wednesday, hitting $1.57. The company had a trading volume of 127,600 shares, compared to its average volume of 1,011,034. Capricor Therapeutics has a fifty-two week low of $0.63 and a fifty-two week high of $4.25.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.07. The company had revenue of $0.31 million during the quarter, compared to the consensus estimate of $1.00 million. The company’s quarterly revenue was down 58.7% on a year-over-year basis. During the same quarter last year, the firm posted ($0.29) earnings per share. research analysts predict that Capricor Therapeutics will post -0.7 EPS for the current year.

Several equities research analysts recently issued reports on the company. ValuEngine upgraded Capricor Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Monday, October 2nd. HC Wainwright boosted their price target on Capricor Therapeutics from $2.15 to $6.50 and gave the company a “buy” rating in a research note on Friday, September 15th.

TRADEMARK VIOLATION NOTICE: This article was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications.

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with's FREE daily email newsletter.